Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Jacobio Pharmaceuticals Group Co's enterprise value is $363.33 Mil.
Jacobio Pharmaceuticals Group Co's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was $-18.17 Mil. Therefore, Jacobio Pharmaceuticals Group Co's EV-to-EBITDA for today is -19.99.
The historical rank and industry rank for Jacobio Pharmaceuticals Group Co's EV-to-EBITDA or its related term are showing as below:
JBPHF'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -60.06 Med: -4.61 Max: 0.89
Current: -20.08
During the past 8 years, the highest EV-to-EBITDA of Jacobio Pharmaceuticals Group Co was 0.89. The lowest was -60.06. And the median was -4.61.
JBPHF's EV-to-EBITDA is ranked worse than 100% of 404
companies
in the Biotechnology industry
Industry Median: 11.82
vs JBPHF: -20.08
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
Jacobio Pharmaceuticals Group Co (OTCPK:JBPHF) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Jacobio Pharmaceuticals Group Co's PE Ratio (TTM) for today is calculated as:
Jacobio Pharmaceuticals Group Co's share price for today is $0.6403.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Jacobio Pharmaceuticals Group Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was $-0.027.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Jacobio Pharmaceuticals Group Co EV-to-EBITDA Chart
JBPHF vs VRTX, REGN, ALNY: EV-to-EBITDA Comparison
For the Biotechnology subindustry, Jacobio Pharmaceuticals Group Co's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Jacobio Pharmaceuticals Group Co EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Jacobio Pharmaceuticals Group Co's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Jacobio Pharmaceuticals Group Co's EV-to-EBITDA falls into.
Jacobio Pharmaceuticals Group Co's current Enterprise Value is $363.33 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Jacobio Pharmaceuticals Group Co's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was $-18.17 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Jacobio Pharmaceuticals Group Co (JBPHF) has a EV-to-EBITDA of -19.99 as of Jul. 26, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Jacobio Pharmaceuticals Group Co. According to the industry distribution chart, Jacobio Pharmaceuticals Group Co ranks #999999 out of 404 companies in the Biotechnology industry.
Is Jacobio Pharmaceuticals Group Co's EV-to-EBITDA too high?
Jacobio Pharmaceuticals Group Co's current EV-to-EBITDA is -19.99. Based on the distribution chart, Jacobio Pharmaceuticals Group Co ranks #999999 out of 404 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Jacobio Pharmaceuticals Group Co has a GF Score™ of 32/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Jacobio Pharmaceuticals Group Co's EV-to-EBITDA compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Jacobio Pharmaceuticals Group Co ranks #999999 out of 404 companies for EV-to-EBITDA. This places Jacobio Pharmaceuticals Group Co in the lower half of its industry. The industry median EV-to-EBITDA is 11.82. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 11.82, based on 404 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Jacobio Pharmaceuticals Group Co. For the Biotechnology industry, the median EV-to-EBITDA is 11.82 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Jacobio Pharmaceuticals Group Co's current EV-to-EBITDA is -19.99. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jacobio Pharmaceuticals Group Co stock overvalued right now?
Based on GuruFocus' analysis, Jacobio Pharmaceuticals Group Co (JBPHF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.30, compared to a current price of $0.64 — trading 113.4% above its estimated fair value. The current EV-to-EBITDA is -19.99. Jacobio Pharmaceuticals Group Co's overall GF Score™ is 32/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Jacobio Pharmaceuticals Group Co (JBPHF), the current EV-to-EBITDA is -19.99 as of Jul. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Jacobio Pharmaceuticals Group Co (JBPHF) Overvalued in 2026?
Based on GuruFocus' analysis, Jacobio Pharmaceuticals Group Co stock appears to be overvalued.
The current stock price of $0.64 is trading 113.4% above its estimated GF Value™ of $0.30.
GuruFocus considers Jacobio Pharmaceuticals Group Co to be Significantly Overvalued.
Key valuation signals for JBPHF:
EV-to-EBITDA: -19.99
GF Value™: $0.30 vs. price of $0.64 (113.4% above fair value)
No single metric tells the full story. See the JBPHF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Jacobio Pharmaceuticals Group Co Business Description
Jacobio Pharmaceuticals Group Co Ltd is a clinical-stage pharmaceutical company focusing on the in-house discovery and development of oncology therapies. The company is engaged in developing breakthrough cancer therapies for patients. The producst pipeline of the company includes KRAS G12C inhibitor, SHP2 inhibitor, Pan-KRAS inhibitor, KRAS G12D ADC JAB-BX600, Aurora Kinase A (AURKA) inhibitor, BET inhibitor, P53 Y220C mutant proteins, and others.
32GF Score
Get the complete analysis for JBPHF
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
JBPHF has been successfully added to your 
